My opinion is that partnership is their preferred strategy - at least for one of FDA or EMA arm...or a strategic investor (Biotech Funds etc).
During 2020 there were a number of references in webinars by Diamond to inbound enquiries....then in the AGM notes there was this:
"Partnering/Corporate engagement: As previously noted, we have received inbound interest from pharmaceutical companies and potential strategic investors in the Company and its programs. To date our approach has been to engage with these groups to explore such interest. It is important to note that such parties can often seek to undertake comprehensive due diligence ahead of any capital injection and/or collaborative commitment..."
The PRV doesn't come into play until we complete P2B successfully - it can help expedite our FDA application....or onsold for $100m.
We'll find out soon.
.
ANP Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
